Literature DB >> 32200292

A bioinformatics and network pharmacology approach to the mechanisms of action of Shenxiao decoction for the treatment of diabetic nephropathy.

Xin Mou1, Di Yi Zhou1, Danyang Zhou1, Kaiyuan Liu1, Li Jun Chen1, Wen Hong Liu2.   

Abstract

BACKGROUND: The epithelial-to-mesenchymal transition (EMT) of renal tubular epithelial cells is the main pathological alteration in diabetic nephropathy (DN). Traditional Chinese medicine (TCM) has been used for the treatment of DN in clinical practice and has been proven to be effective.
PURPOSE: This aim of this study was to shed light on the efficacy of Shenxiao decoction (SXD) on the EMT of renal tubular epithelial cells and the molecular mechanisms of SXD in mice with DN, as well as on the high glucose (HG)- and TGF-β1-induced EMT of NRK-52E and HK-2 cells. STUDY DESIGN AND METHODS: A bioinformatics and network pharmacology method were utilized to construct the active ingredient-target networks of SXD that were responsible for the beneficial effects against DN. The effects of RUNX3 were validated in HG- and TGF-β1-induced EMT processes in NRK-52E and HK-2 cells.
RESULTS: Bioinformatics analysis revealed that 122 matching targets were closely associated with the regulation of cell migration and the AGE-RAGE signaling pathway in diabetic complications. The results also revealed that, relative to the mice with DN, the mice in the treatment group had an improved general state and reduced blood glucose levels. The degradation of renal function was ameliorated by SXD. Moreover, the protective effects of SXD were also observed on renal structural changes. Furthermore, SXD suppressed the activation of the transforming growth factor (TGF)-β1/Smad pathway and upregulated the RUNX3 and E-cadherin levels and downregulated the extracellular matrix (ECM) protein levels in mice with DN. SXD was further found to prevent the HG- and TGF-β1-induced EMT processes in NRK-52E and HK-2 cells. Additionally, the overexpression of RUNX3 markedly inhibited the EMT and TGF-β1/Smad pathway induced by HG and TGF-β1 in NRK-52E and HK-2 cells.
CONCLUSION: Taken together, these results suggest that SXD maybe alleviate EMT in DN via the inhibition of the TGF-β1/Smad/RUNX3 signaling pathway under hyperglycemic conditions.
Copyright © 2020 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Bioinformatics and network pharmacology; Diabetic nephropathy; Epithelial-to-mesenchymal transition; RUNX3; Shenxiao decoction

Year:  2020        PMID: 32200292     DOI: 10.1016/j.phymed.2020.153192

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  12 in total

1.  An in silico and in vitro integrated analysis method to reveal the curative mechanisms and pharmacodynamic substances of Bufei granule on chronic obstructive pulmonary disease.

Authors:  Yuan-Yuan Ma; Rong Li; Zhi-Xian Shang; Wei Liu; Xin-Yi Jiao; Liu-Yi Liang; Rui Liu; Zheng Li
Journal:  Mol Divers       Date:  2022-03-09       Impact factor: 2.943

2.  A Network Pharmacology Approach to Explore the Mechanism of HuangZhi YiShen Capsule for Treatment of Diabetic Kidney Disease.

Authors:  Xue-Feng Zhou; Wei-E Zhou; Wen-Jing Liu; Min-Jing Luo; Xia-Qing Wu; Ying Wang; Peng Liu; Yu-Min Wen; Jia-Lin Li; Ting-Ting Zhao; Hao-Jun Zhang; Hai-Ling Zhao; Ping Li
Journal:  J Transl Int Med       Date:  2021-06-18

3.  Integrating Network Pharmacology and Experimental Validation to Investigate the Mechanisms of Huazhuojiedu Decoction to Treat Chronic Atrophic Gastritis.

Authors:  Xinyu Hao; Yu Liu; Pingping Zhou; Qian Jiang; Zeqi Yang; Miaochan Xu; Shaowei Liu; Shixiong Zhang; Yangang Wang
Journal:  Evid Based Complement Alternat Med       Date:  2020-12-07       Impact factor: 2.629

4.  Investigating the Mechanisms of Pollen Typhae in the Treatment of Diabetic Retinopathy Based on Network Pharmacology and Molecular Docking.

Authors:  Rongrong Zhou; Yuqing Zhang; Liyun Duan; Yuehong Zhang; Yingying Duan; Xiaomin Kang; Fengmei Lian
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-03       Impact factor: 2.629

5.  Investigation of the active ingredients and pharmacological mechanisms of Porana sinensis Hemsl. Against rheumatoid arthritis using network pharmacology and experimental validation.

Authors:  Jing Hu; Lintao Zhao; Ning Li; Yuanyuan Yang; Tong Qu; Hui Ren; Xiaomin Cui; Hongxun Tao; Zhiyong Chen; Yu Peng
Journal:  PLoS One       Date:  2022-03-02       Impact factor: 3.240

6.  A network pharmacology approach to predict potential targets and mechanisms of "Ramulus Cinnamomi (cassiae) - Paeonia lactiflora" herb pair in the treatment of chronic pain with comorbid anxiety and depression.

Authors:  Hao-Tian Pan; Zi-Qi Xi; Xu-Qiang Wei; Ke Wang
Journal:  Ann Med       Date:  2022-12       Impact factor: 4.709

7.  The TCM Preparation Feilike Mixture for the Treatment of Pneumonia: Network Analysis, Pharmacological Assessment and Silico Simulation.

Authors:  Juqin Peng; Xiaoxiao Chen; Min Hou; Kuo Yang; Bing Yang; Pan Wang; Yang Du; Qingyuan Yu; Junguo Ren; Jianxun Liu
Journal:  Front Pharmacol       Date:  2022-02-28       Impact factor: 5.810

8.  Quantitative assessment of renal damage in rhesus monkeys with diabetic nephropathy using contrast-enhanced ultrasound.

Authors:  Wenwu Ling; Yulan Peng; Hong Wang; Xingxing An; Yanrong Lu
Journal:  Ann Transl Med       Date:  2022-03

9.  Systems pharmacological study illustrates the immune regulation, anti-infection, anti-inflammation, and multi-organ protection mechanism of Qing-Fei-Pai-Du decoction in the treatment of COVID-19.

Authors:  Jing Zhao; Saisai Tian; Dong Lu; Jian Yang; Huawu Zeng; Feng Zhang; Dongzhu Tu; Guangbo Ge; Yuejuan Zheng; Ting Shi; Xin Xu; Shiyi Zhao; Yili Yang; Weidong Zhang
Journal:  Phytomedicine       Date:  2020-09-09       Impact factor: 5.340

10.  Huoxue Jiedu Huayu Formula Alleviates Cell Pyroptosis in Contralateral Kidneys of 6-Month-Old UUO Rats through the NLRP3/Caspase-1/IL-1β Pathway.

Authors:  Xuelian Ma; Panpan Qiang; Gege Chen; Zheng Wang; Xiangting Wang; Qingyou Xu
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-12       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.